Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$59.78

-0.7252 (-1.20%)

, AZN

AstraZeneca

$26.70

-0.4 (-1.48%)

10:01
11/28/16
11/28
10:01
11/28/16
10:01

Citi analyst 'perturbed,' downgrades AbbVie to Neutral

Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.

ABBV

AbbVie

$59.78

-0.7252 (-1.20%)

AZN

AstraZeneca

$26.70

-0.4 (-1.48%)

LLY

Eli Lilly

$67.85

-1.2686 (-1.84%)

BMY

Bristol-Myers

$56.76

-0.22 (-0.39%)

  • 29

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 16

    Feb

ABBV AbbVie
$59.78

-0.7252 (-1.20%)

11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.
11/07/16
COWN
11/07/16
NO CHANGE
Target $45
COWN
Outperform
Coherus has other paths to pursue in AbbVie patent fight, says Cowen
Cowen analyst Ken Cacciatore noted the U.S. Patent Trial and Appeals Board decided to deny institution of Coherus Biosciences' (CHRS) Inter Partes Review against AbbVie's (ABBV) '166 patent related to Humira, though he believes that Coherus still has other remaining pathways in its patent fight over the drug. "Today's news, although a setback, should be treated as a relatively minor" one, he tells investors. Cacciatore has an Outperform rating and $45 price target on Coherus shares.
11/07/16
SBSH
11/07/16
NO CHANGE
Target $36
SBSH
Buy
Citi says buy Coherus Biosciences on today's selloff
Citi analyst Mohit Bansal recommends using today's selloff in shares of Coherus Biosciences (CHRS) as a buying opportunity. Checks with patent experts indicate that the patent in today's case is not a key obstacle against a biosimilar of AbbVie's Humira, Bansal tells investors in a research note. Further, the analyst estimates fair value of Coherus shares at $24 if the Humira biosimilar is removed completely. The stock is currently down 16%, or $4.60, to $23.55. Basel does not expect a biosimilar launch until 2020. He adds that every one year launch delay post 2020 would impact his fair value for shares by only $1. The analyst keeps a Buy rating on Coherus with a $36 price target.
11/28/16
SBSH
11/28/16
DOWNGRADE
SBSH
Neutral
AbbVie downgraded to Neutral from Buy at Citi
AZN AstraZeneca
$26.70

-0.4 (-1.48%)

10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
LLY Eli Lilly
$67.85

-1.2686 (-1.84%)

11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.
11/25/16
ATLE
11/25/16
DOWNGRADE
ATLE
Neutral
Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities
11/28/16
BOFA
11/28/16
NO CHANGE
BOFA
Buy
Eli Lilly removed from US 1 List at BofA/Merrill
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
BMY Bristol-Myers
$56.76

-0.22 (-0.39%)

11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
HDLY
10/28/16
UPGRADE
HDLY
Long-Term Buy
Bristol-Myers upgraded to Long-Term Buy from Neutral at Hilliard Lyons

TODAY'S FREE FLY STORIES

TOL

Toll Brothers

$30.09

0.77 (2.63%)

13:38
12/05/16
12/05
13:38
12/05/16
13:38
Technical Analysis
Toll Brothers technical comments before earnings, potential bullish pattern »

There is a potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

13:35
12/05/16
12/05
13:35
12/05/16
13:35
General news
NY Fed's overnight reverse repo totaled $168.4 B, with 51 counterparties »

NY Fed's overnight…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

13:31
12/05/16
12/05
13:31
12/05/16
13:31
Hot Stocks
FMC Technologies, Technip shareholders approve business combination »

FMC Technologies (FTI)…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

NVS

Novartis

$69.06

0.89 (1.31%)

13:26
12/05/16
12/05
13:26
12/05/16
13:26
Hot Stocks
Novartis' MPN survey results 'help quantify' daily difficulty of MPN »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AXP

American Express

$72.24

0.38 (0.53%)

13:25
12/05/16
12/05
13:25
12/05/16
13:25
Hot Stocks
Barclays turns focus on American Express toward enterprise strength »

Research firm Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CBS

CBS

$61.26

1.075 (1.79%)

, T

AT&T

$38.81

0.2 (0.52%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
CBS CEO: AT&T will not get Showtime for $5 a month »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.26

1.075 (1.79%)

T

AT&T

$38.81

0.2 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

FRBK

Republic First Bancorp

$5.35

-0.05 (-0.93%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
Republic First Bancorp elects Vernon Hill as chairman »

Republic First Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$61.25

1.07 (1.78%)

, T

AT&T

$38.79

0.18 (0.47%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Hot Stocks
CBS CEO says will make deal with DirecTV online »

CBS (CBS) CEO Leslie…

CBS

CBS

$61.25

1.07 (1.78%)

T

AT&T

$38.79

0.18 (0.47%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 15

    Jan

YUM

Yum! Brands

$63.07

0.65 (1.04%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Options
3X average daily option volume in Yum Brands as players gobble up Jan 65 calls »

3X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CBS

CBS

$61.24

1.055 (1.75%)

, T

AT&T

$38.80

0.185 (0.48%)

13:19
12/05/16
12/05
13:19
12/05/16
13:19
Hot Stocks
CBS CEO says in discussions over DirecTV NOW »

Says industry needs total…

CBS

CBS

$61.24

1.055 (1.75%)

T

AT&T

$38.80

0.185 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

$NYE

NYSE Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

, SNY

Sanofi

$40.79

0.77 (1.92%)

13:15
12/05/16
12/05
13:15
12/05/16
13:15
Hot Stocks
Alnylam 'pleased' with updated ALN-CC5 Phase 1/2 trial results »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

SNY

Sanofi

$40.79

0.77 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

DPZ

Domino's Pizza

$168.06

0.06 (0.04%)

13:14
12/05/16
12/05
13:14
12/05/16
13:14
Hot Stocks
Domino's locations throughout Phoenix to hire 300 new team members »

Domino's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

CYNO

Cynosure

$44.35

-0.7 (-1.55%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Conference/Events
Cynosure management to meet with Maxim »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
Global Blood Therapeutics announces details on PRO tool in phase 3 HOPE study »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CBS

CBS

$61.09

0.905 (1.50%)

, NFLX

Netflix

$120.81

3.59 (3.06%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
CBS' Moonves: 2017 will be 'very strong year' for company »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.09

0.905 (1.50%)

NFLX

Netflix

$120.81

3.59 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

CSIQ

Canadian Solar

$11.07

-0.21 (-1.86%)

13:10
12/05/16
12/05
13:10
12/05/16
13:10
Options
Calls active in Canadian Solar as shares see relative strength »

Calls active in Canadian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

COST

Costco

$152.09

0.35 (0.23%)

13:08
12/05/16
12/05
13:08
12/05/16
13:08
Periodicals
Ontario regulator investigating Costco allegations, STAT reports »

Ontario's Ministry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Hot Stocks
Seattle Gen.: Patients in ADCETRIS trial achieve significant durable remissions »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SMCI

Super Micro Computer

$27.00

0.8 (3.05%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Conference/Events
Super Micro Computer management to meet with Maxim »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Feb

  • 09

    Feb

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

13:04
12/05/16
12/05
13:04
12/05/16
13:04
Hot Stocks
Juno announces 'encouraging' preliminary JCAR017 clinical data for NHL patients »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

13:04
12/05/16
12/05
13:04
12/05/16
13:04
Hot Stocks
Bellicum Pharmaceuticals announces GoCAR-T, GoTCR presentations at meeting »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CBS

CBS

$61.03

0.85 (1.41%)

, VIA

Viacom

$40.35

-1 (-2.42%)

13:02
12/05/16
12/05
13:02
12/05/16
13:02
Hot Stocks
CBS CEO: Company 'very happy' as standalone group »

CBS (CBS) chairman and…

CBS

CBS

$61.03

0.85 (1.41%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

UAL

United Continental

$68.28

-0.99 (-1.43%)

13:02
12/05/16
12/05
13:02
12/05/16
13:02
Hot Stocks
United Continental technicians ratify joint collective bargaining agreement »

United Airlines announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.